CRISPR Therapeutics AG — Director's Dealing 2019

Nov 21, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2019-11-19

Reporting Person: CAGNONI PABLO J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-11-19	Common Shares	M	7500	$5.59	Acquired	7500	Direct
2019-11-19	Common Shares	S	7500	$62.00	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-11-19	Stock Option (Right to Buy)	$5.59	M	7500	Disposed	2025-11-04	Common Shares (7500)	Direct

Footnotes

F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This option was granted on November 4, 2015 with respect to 93,833 Common Shares with 100% of the shares vesting in 48 equal monthly installments thereafter.